iBio's GAAP loss for 6 months of fiscal year 2022 was $20.86 million, up 33.2% from $15.665 million in the prior year. Revenue declined 2.9 times to $0.379 million from $1.115 million a year earlier.
iBio's GAAP loss for 6 months of fiscal year 2022 was $20.86 million, up 33.2% from $15.665 million in the prior year. Revenue declined 2.9 times to $0.379 million from $1.115 million a year earlier. 
ir.ibioinc.com
English (US) 